| Dr Kylie Rae Madsen, AUD | |
|
415 Joshua Dr, Kaysville, UT 84037-9544 | |
| (801) 589-2612 | |
| Not Available |
| Full Name | Dr Kylie Rae Madsen |
|---|---|
| Gender | Female |
| Speciality | Audiologist |
| Location | 415 Joshua Dr, Kaysville, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003535238 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | (Utah) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kylie Rae Madsen, AUD 415 Joshua Dr, Kaysville, UT 84037-9544 Ph: (801) 589-2612 | Dr Kylie Rae Madsen, AUD 415 Joshua Dr, Kaysville, UT 84037-9544 Ph: (801) 589-2612 |
News Archive
As electronic health record systems become more interconnected, errors may propagate much farther than under old paper-based systems, a recent study suggested. According to a review by the Pennsylvania Patient Safety Authority, mistakes and near misses involving electronic health records were analogous to those made with paper-based records with one caveat: those made with EHRs tend to be amplified and can affect a larger group of people.
MorphoSys AG and Immatics Biotechnologies GmbH announced today a strategic alliance to generate novel antibody-based therapeutics against multiple proprietary cancer antigens recognized by T cells.
Coffee increases the risk of prediabetes in young adults with hypertension who are slow caffeine metabolisers, according to results from the HARVEST study presented at ESC Congress today by Dr Lucio Mos from Italy. People who drank more than three cups of coffee per day doubled their risk of prediabetes.
Dicerna Pharmaceuticals, Inc., a second generation RNA interference company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA molecules, today announced that it has closed a $25 million Series B round of financing. New investor Domain Associates led the round, with all existing investors participating - Oxford Bioscience Partners, Skyline Ventures and Abingworth.
Patients with heart disease in Norway, a country with no fortification of foods with folic acid, had an associated increased risk of cancer and death from any cause if they had received treatment with folic acid and vitamin B12, according to a study in the November 18 issue of JAMA.
› Verified 4 days ago